Latanmono Conserveermiddelvrij

Latanoprost, the active ingredient in Latanmono Conserveermiddelvrij, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension by increasing uveoscleral outflow of aqueous humor, thereby helping to preserve visual function.

GNH USA supplies Latanmono Conserveermiddelvrij as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost belongs to the prostaglandin analog class and is used to manage conditions that require reduction of intra‑ocular pressure.

Open‑angle glaucoma: lowers eye pressure to prevent optic nerve damage. Ocular hypertension: reduces elevated eye pressure to lower the risk of developing glaucoma. Normal‑tension glaucoma: helps maintain intra‑ocular pressure within a normal range to protect visual function.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and density. - Darkening of the iris color. - Mild eye irritation or foreign‑body sensation. - Transient blurred vision after instillation. - Temporary eye discomfort.

Serious or Rare Side Effects: - Severe allergic reaction with swelling or pain. - Uveitis or intra‑ocular inflammation. - Macular edema leading to vision changes. - Sudden loss of vision. - Ocular infection requiring medical attention.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for adverse events.

Assess intra‑ocular pressure before starting treatment. Monitor iris color changes during therapy. Avoid use in eyes with active inflammation or infection. Inform patients about possible eyelash growth and iris darkening. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory eye drops: may diminish pressure‑lowering effect. - Concurrent prostaglandin analogs: increase risk of additive side effects. - Systemic carbonic anhydrase inhibitors: could alter intra‑ocular pressure control.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: may produce additive IOP reduction. - Alpha‑adrenergic agonists: potential enhanced pressure‑lowering. - Topical corticosteroids: may increase risk of ocular side effects.